Found: 7
Select item for more details and to access through your institution.
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2007, v. 9, n. 2, p. 194, doi. 10.1111/j.1463-1326.2006.00704.x
- By:
- Publication type:
- Article
Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug.
- Published in:
- Diabetes, Obesity & Metabolism, 2007, v. 9, n. 2, p. 153, doi. 10.1111/j.1463-1326.2007.00705.x
- By:
- Publication type:
- Article
Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2007, v. 9, n. 2, p. 175, doi. 10.1111/j.1463-1326.2006.00698.x
- By:
- Publication type:
- Article
News and Views.
- Published in:
- Diabetes, Obesity & Metabolism, 2007, v. 9, n. 2, p. 206, doi. 10.1111/j.1463-1326.2006.00702.x
- By:
- Publication type:
- Article
Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.
- Published in:
- Diabetes, Obesity & Metabolism, 2007, v. 9, n. 2, p. 166, doi. 10.1111/j.1463-1326.2006.00684.x
- By:
- Publication type:
- Article
Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and β-cell function in patients with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2007, v. 9, n. 2, p. 186, doi. 10.1111/j.1463-1326.2006.00691.x
- By:
- Publication type:
- Article
A triumph for physiology driving drug discovery: the potential impact of dipeptidyl peptidase-IV inhibitors in type 2 diabetes.
- Published in:
- 2007
- By:
- Publication type:
- Editorial